• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    National Philanthropic Trust Welcomes Three Board Members

    1/3/24 9:30:00 AM ET
    $BANR
    $HLNE
    $OCGN
    Major Banks
    Finance
    Investment Managers
    Finance
    Get the next $BANR alert in real time by email

    Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth join the Board of Trustees at the largest national, independent donor-advised fund public charity

    National Philanthropic Trust (NPT), the largest national, independent public charity that manages donor-advised funds, and one of the leading grantmaking institutions in the U.S., is pleased to announce the appointment of Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth to its Board of Trustees.

    "As NPT continues to grow, innovate, and advance philanthropy around the world, we welcome these three accomplished professionals to our Board of Trustees," said Eileen Heisman, CEO of National Philanthropic Trust. "NPT is now the third largest grantmaking organization in the world. With esteemed careers in private market investing, technology, law, and philanthropy, Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth will make welcome additions to our board."

    Jeffrey Armbrister is an executive with more than 25 years of transaction-based investing and operational experience. He is the Chief Financial Officer of Hamilton Lane (NASDAQ:HLNE), a global private markets investment management firm.

    Armbrister previously served as the company's Global Head of Direct Equity Investments, where he was responsible for direction and oversight of the firm's direct equity and co-investment platform. His role included service on the boards of directors of companies in which Hamilton Lane invested on behalf of clients.

    Prior to joining Hamilton Lane, Armbrister served as Managing Director for Versa Capital Management, where he focused on making control-oriented, special situations, debt and equity investments in middle market companies across a variety of industries. While at Versa, he participated in all major investment functions, providing oversight for certain finance-related operational activities, including financial analysis and reporting and cash flow management for several portfolio companies.

    Prior to joining Versa, Armbrister was an Equity Research analyst at Oppenheimer + Close. He has also held private equity, venture capital, corporate development, and investment banking positions at Berwind Financial Group, Redleaf Group, ICG Commerce, and Wheat First Butcher Singer, respectively. He currently serves on the board of directors or similar bodies of several charitable organizations. Armbrister received his Bachelor of Arts in Economics from the University of Virginia.

    Lindy Benton-Moreno, an accomplished leader and sought-after speaker, has devoted her 30-year healthcare IT career to advancing technology and inspiring leaders. As an Executive Board Chair of Vyne, Benton-Moreno fueled the growth of a small dental company by establishing a thriving medical division.

    She was named by Health Data Management among the "Most Powerful Women in Healthcare IT" and recognized on Becker's "Women Power Players Health IT" list. As a Fellow at the Health Information and Management Systems Society, she engages with executive councils across health-related committees and industry associations.

    With a Master of Science from Florida State University, Benton-Moreno became a Distinguished Alumnus in Business and Industry, serving on the university's National Board of Directors as the university Alumni Association's National Director. Prior to entering healthcare IT, she pioneered the mainstreaming of 100+ children with disabilities into Florida's public schools and the sponsoring of scholarships for first-generation college students, an initiative close to her heart.

    Connie Collingsworth is an experienced board member with expertise in governance, risk management, executive compensation, and complex investments for publicly traded companies, private companies, and private equity funds. Her board experience includes leadership positions on public and private company boards as well as charitable organizations.

    Collingsworth's current board roles include Banner Corporation (NASDAQ:BANR) and Axxes Capital. She also serves as a Board Advisor to European private equity fund Planet First Partners, a Business Advisory Board Member to biotech company Ocugen (NASDAQ:OCGN), and a Strategic Advisor to venture fund LoudCapital.

    Collingsworth is the former Chief Operating Officer of the Bill & Melinda Gates Foundation, the largest private foundation in the world with over $65 billion in assets, distributing over $8.3 billion annually. During her 22-year tenure, she was responsible for managing and scaling the foundation's business operations globally. She also served as Chief Legal Officer, advising Bill Gates, Melinda French Gates, and Warren Buffett on governance, including creating the foundation's Governing Board. She was the architect of the foundation's IP philosophy and led the foundation's work in collaborating with for-profit companies, including big pharma and companies in the biotech and ed-tech sectors.

    Collingsworth holds a Master of Laws in International Business Studies from the University of Exeter, England, a Juris Doctorate from the University of Nebraska, and a Bachelor of Arts from Andrews University.

    About National Philanthropic Trust

    Founded in 1996, National Philanthropic Trust (NPT) is the largest national, independent public charity that manages donor-advised funds and one of the leading grantmaking institutions in the U.S. Since its founding, NPT has raised more than $49.8 billion in charitable funding and has made more than 640,000 grants exceeding $25.7 billion to nonprofits around the world. NPT annually publishes the Donor-Advised Fund Report, the sector's authority on the state of DAF philanthropy. Visit NPT's resource library to learn what you can do with a DAF and about NPT's impact investing options. More at NPTrust.org and NPTGivingPoint.org.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240103652385/en/

    Get the next $BANR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BANR
    $HLNE
    $OCGN

    CompanyDatePrice TargetRatingAnalyst
    Hamilton Lane Incorporated
    $HLNE
    11/6/2025$165.00Neutral → Buy
    Goldman
    Hamilton Lane Incorporated
    $HLNE
    10/14/2025$181.00Perform → Outperform
    Oppenheimer
    Hamilton Lane Incorporated
    $HLNE
    10/13/2025$150.00Mkt Perform → Outperform
    Keefe Bruyette
    Hamilton Lane Incorporated
    $HLNE
    10/3/2025$150.00Outperform
    BMO Capital Markets
    Hamilton Lane Incorporated
    $HLNE
    9/18/2025$162.00Sell → Neutral
    Goldman
    Hamilton Lane Incorporated
    $HLNE
    5/15/2025Outperform → Perform
    Oppenheimer
    Banner Corporation
    $BANR
    4/21/2025$71.00Neutral → Buy
    Janney
    Hamilton Lane Incorporated
    $HLNE
    1/21/2025$186.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $BANR
    $HLNE
    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hamilton Lane Strengthens North America Client Solutions Team, Appointing Seven Senior Members

    CONSHOHOCKEN, Pa., Nov. 10, 2025 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (NASDAQ:HLNE) today announced multiple senior appointments to its North American client solutions team, supporting both institutional and private wealth outreach. Beth Nardi joins as Head of U.S. Private Wealth, leading the firm's Private Wealth Solutions business, setting strategic direction and overseeing the delivery of both evergreen and traditional private markets offerings tailored to the evolving needs of high-net-worth investors and their advisors. She brings more than two decades of experience in the asset management industry, most recently serving as Head of Enterprise

    11/10/25 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Ocugen Provides Business Update with Third Quarter 2025 Financial Results

    Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA) Executed licensing agreement with Kwangdong Pharmaceutical for exclusive rights in South Korea to OCU400 Sales milestones of $1.5 million for every $15 million of sales in South Korea, projected to reach $180 million or more in first 10 years of commercialization and royalties equaling 25% of net sales Closed $20 million registered direct offering of common stock and accompanying premi

    11/5/25 6:30:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HAMILTON LANE INCORPORATED REPORTS SECOND QUARTER FISCAL 2026 RESULTS

    CONSHOHOCKEN, Pa., Nov. 4, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the second fiscal quarter ended September 30, 2025. The Company issued a full detailed presentation of its second quarter fiscal 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/. Dividend Hamilton Lane has declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on December 19, 2025 that will be paid on January 7, 2026. The target full-year dividend of $2.16 represents a 10% increase from the prior fisca

    11/4/25 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    SEC Filings

    View All

    SEC Form S-8 filed by Banner Corporation

    S-8 - BANNER CORP (0000946673) (Filer)

    11/5/25 5:19:16 PM ET
    $BANR
    Major Banks
    Finance

    SEC Form 10-Q filed by Ocugen Inc.

    10-Q - Ocugen, Inc. (0001372299) (Filer)

    11/5/25 9:41:30 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Ocugen, Inc. (0001372299) (Filer)

    11/5/25 7:30:48 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BANR
    $HLNE
    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Delgado-Moreira Juan bought $1,042,832 worth of shares (8,000 units at $130.35), increasing direct ownership by 0.61% to 1,314,447 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    11/10/25 8:20:49 PM ET
    $HLNE
    Investment Managers
    Finance

    Director Tracey Millicent C. was granted 782 shares (SEC Form 4)

    4 - BANNER CORP (0000946673) (Issuer)

    11/5/25 12:16:34 PM ET
    $BANR
    Major Banks
    Finance

    Executive VP, Banner Bank Oxford Daniel Everett was granted 1,846 shares, increasing direct ownership by 41% to 6,316 units (SEC Form 4)

    4 - BANNER CORP (0000946673) (Issuer)

    11/5/25 12:03:06 PM ET
    $BANR
    Major Banks
    Finance

    $BANR
    $HLNE
    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BANR
    $HLNE
    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Co-Chief Executive Officer Delgado-Moreira Juan bought $1,042,832 worth of shares (8,000 units at $130.35), increasing direct ownership by 0.61% to 1,314,447 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    11/10/25 8:20:49 PM ET
    $HLNE
    Investment Managers
    Finance

    Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    12/2/24 4:15:25 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    11/26/24 4:50:10 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hamilton Lane upgraded by Goldman with a new price target

    Goldman upgraded Hamilton Lane from Neutral to Buy and set a new price target of $165.00

    11/6/25 8:41:24 AM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $181.00

    10/14/25 8:37:36 AM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane upgraded by Keefe Bruyette with a new price target

    Keefe Bruyette upgraded Hamilton Lane from Mkt Perform to Outperform and set a new price target of $150.00

    10/13/25 8:40:10 AM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Leadership Updates

    Live Leadership Updates

    View All

    Hamilton Lane and Guardian Announce Long-Term Strategic Partnership

    CONSHOHOCKEN, Pa. and NEW YORK, Nov. 3, 2025 /PRNewswire/ -- Leading private markets firm Hamilton Lane (NASDAQ:HLNE) and The Guardian Life Insurance Company of America® ("Guardian"), one of the nation's largest life insurers and a leading provider of employee benefits, today announced an innovative, long-term strategic partnership. Through this partnership, Hamilton Lane will manage Guardian's existing private equity portfolio of nearly $5 billion. Guardian will also commit to invest approximately $500 million per year in private equity for the next 10 years through Hamilton Lane. This commitment maintains Guardian's typical annual contribution to the asset class and supports its general a

    11/3/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs

    -- Experienced Industry Leader to drive Cosette's Best-in-Class Quality Organization and facilitate Regulatory Approvals -- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630266171/en/Jeff Neubig, VP, Quality & Regulatory Affairs, Cosette Pharmaceuticals In this critical role, Jeff will lead Cosette's best-in-class quality and regulatory affairs organizations, maintaining the company's rigorous quality standards and further establishing Co

    6/30/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

    Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I

    4/23/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Financials

    Live finance-specific insights

    View All

    HAMILTON LANE INCORPORATED REPORTS SECOND QUARTER FISCAL 2026 RESULTS

    CONSHOHOCKEN, Pa., Nov. 4, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the second fiscal quarter ended September 30, 2025. The Company issued a full detailed presentation of its second quarter fiscal 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/. Dividend Hamilton Lane has declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on December 19, 2025 that will be paid on January 7, 2026. The target full-year dividend of $2.16 represents a 10% increase from the prior fisca

    11/4/25 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

    MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, November 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events section of

    10/23/25 7:30:30 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Banner Corporation Reports Net Income of $53.5 Million, or $1.54 Per Diluted Share, for Third Quarter 2025; Increases Quarterly Cash Dividend Declared by 4% to $0.50 Per Share

    Banner Corporation (NASDAQ:BANR) ("Banner"), the parent company of Banner Bank, today reported net income of $53.5 million, or $1.54 per diluted share, for the third quarter of 2025, compared to $45.5 million, or $1.31 per diluted share, for the preceding quarter and $45.2 million, or $1.30 per diluted share, for the third quarter of 2024. Net interest income was $150.0 million for the third quarter of 2025, compared to $144.4 million in the preceding quarter and $135.7 million for the third quarter a year ago. The increase in net interest income compared to the preceding quarter and the prior year quarter reflects an increase in both the yield and average balance of interest-earning assets

    10/15/25 4:00:00 PM ET
    $BANR
    Major Banks
    Finance

    $BANR
    $HLNE
    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/13/24 9:56:40 PM ET
    $HLNE
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

    SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

    11/12/24 4:59:47 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/12/24 3:55:46 PM ET
    $HLNE
    Investment Managers
    Finance